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ABSTRACT Four different vaccine platforms, each targeting the human malaria para-
site Plasmodium vivax cell-traversal protein for ookinetes and sporozoites (PvCelTOS),
were generated and assessed for protective efﬁcacy. These platforms consisted of a re-
combinant chimpanzee adenoviral vector 63 (ChAd63) expressing PvCelTOS (Ad), a re-
combinant modiﬁed vaccinia virus Ankara expressing PvCelTOS (MVA), PvCelTOS conju-
gated to bacteriophage Q virus-like particles (VLPs), and a recombinant PvCelTOS
protein expressed in eukaryotic HEK293T cells (protein). Inbred BALB/c mice and out-
bred CD-1 mice were immunized using the following prime-boost regimens: Ad-
MVA, Ad-VLPs, and Ad-protein. Protective efﬁcacy against sporozoite challenge was
assessed after immunization using a novel chimeric rodent Plasmodium berghei para-
site (Pb-PvCelTOS). This chimeric parasite expresses P. vivax CelTOS in place of the
endogenous P. berghei CelTOS and produces fully infectious sporozoites. A single Ad
immunization in BALB/c and CD-1 mice induced anti-PvCelTOS antibodies which
were boosted efﬁciently using MVA, VLP, or protein immunization. PvCelTOS-speciﬁc
gamma interferon- and tumor necrosis factor alpha-producing CD8 T cells were in-
duced at high frequencies by all prime-boost regimens in BALB/c mice but not in
CD-1 mice; in CD-1 mice, they were only marginally increased after boosting with
MVA. Despite the induction of anti-PvCelTOS antibodies and PvCelTOS-speciﬁc CD8
T-cell responses, only low levels of protective efﬁcacy against challenge with Pb-
PvCelTOS sporozoites were obtained using any immunization strategy. In BALB/c
mice, no immunization regimens provided signiﬁcant protection against a Pb-
PvCelTOS chimeric sporozoite challenge. In CD-1 mice, modest protective efﬁcacy
against challenge with chimeric P. berghei sporozoites expressing either PvCelTOS or
P. falciparum CelTOS was observed using the Ad-protein vaccination regimen.
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Plasmodium vivax is the most widely distributed human malaria parasite in the world.It is a major health risk to 2.85 billion people and is considered the most difﬁcult
species of malaria parasite to control and eliminate from regions of endemicity (1). This
is largely due to the parasite’s ability to remain latent in the liver of infected people,
reactivating weeks or even years after an initial infection (2, 3). As with Plasmodium
falciparum, no effective vaccine offering protection against P. vivax infection has yet
been licensed. The preerythrocytic stage (sporozoite and infected liver stage) continues
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to be the most attractive target for vaccine development (4). The most advanced
vaccine against P. falciparum is RTS,S/AS01, which aims to prevent infection by stimu-
lating immune responses against the major Plasmodium sporozoite surface antigen
circumsporozoite protein (CSP). A phase III trial of RTS,S/AS01 conducted at 11 sites in
seven African countries demonstrated 28% efﬁcacy for 5- to 17-month-old children and
18% efﬁcacy for 6- to 12-week-old infants with three doses over the entire course of the
study (3 to 4 years of follow-up) (5).
Despite the difﬁculty in testing P. vivax vaccine candidates in controlled human
infection studies, P. vivax CSP (PvCSP) is also being actively investigated as a preeryth-
rocytic stage vaccine (6–9). Various vaccine platforms and strategies have been tested,
and protective efﬁcacy against infection has been demonstrated in nonhuman primates
(10) and in immunized mice using chimeric rodent malaria parasites expressing PvCSP
(11, 12).
While the protective efﬁcacy of RTS,S/AS01 is encouraging, improvements will be
necessary to induce higher levels of protective immunity as well as broad strain-
transcending immunity. A strategy for increasing the effectiveness of subunit malaria
vaccines is the use of formulations that incorporate multiple parasite antigens targeting
several stages of the parasite cycle (13). A number of studies have sought to identify
alternative sporozoite antigens to CSP that similarly induce protective immunity. One
candidate antigen is the cell-traversal protein for ookinetes and sporozoites (CelTOS), a
secretory microneme protein that is required for parasite traversal of host cells both for
ookinetes in the mosquito and for sporozoites (14). In studies using peripheral blood
mononuclear cells (PBMCs) from volunteers immunized with irradiated P. falciparum
sporozoites, the ex vivo gamma interferon (IFN-) enzyme-linked immunosorbent spot
assay responses induced by P. falciparum CelTOS (PfCelTOS) peptides correlated the
best with protection in volunteers (15). Anti-PfCelTOS antibodies have been shown to
inhibit sporozoite motility and invasion of hepatocytes in vitro, and immunization of
mice with recombinant PfCelTOS has induced sterile protection against a heterologous
challenge with P. berghei sporozoites (16, 17). Immunization of mice with live-
attenuated Shigella expressing the rodent Plasmodium berghei CelTOS (PbCelTOS) has
been shown to induce protective efﬁcacy against P. berghei sporozoite challenge (18).
In addition, a DNA vaccine coding for PfCelTOS has been shown to induce humoral and
cellular responses against the protein in mice and nonhuman primates (19).
In contrast to PfCelTOS, studies investigating P. vivax CelTOS (PvCelTOS) as a
potential preerythrocytic stage vaccine candidate have not yet been reported. Our
interest in this candidate came from reports of its good immunogenicity and protective
efﬁcacy against infection in rodent models as well as from the conserved nature of
PvCelTOS, with some evidence of cross-species protection being provided (17, 20). In
this study, we report on the generation and analysis of four different clinically relevant
vaccine platforms to target PvCelTOS. These platforms are based on previous studies
targeting various vaccine candidate antigens in both P. falciparum and P. vivax. The
recombinant chimpanzee adenoviral (Ad) vector 63 (ChAd63) and modiﬁed vaccinia
virus Ankara (MVA) vectors have proven effective in generating protective immunity
against a variety of antigens in animal models and in humans (21). An initial prime
immunization with ChAd63 expressing a Plasmodium antigen followed by a boost
immunization with MVA expressing the same parasite antigen has been shown to elicit
exceptionally high antigen-speciﬁc T-cell responses (22). Virus-like particles (VLPs) are
self-assembly systems that spontaneously form virus-shaped particles following expres-
sion of one or more viral proteins (23). RTS,S, for example, is a VLP based on the
hepatitis B surface antigen (24). VLPs are able to induce strong B-cell responses in the
absence of adjuvants by efﬁciently cross-linking speciﬁc receptors on B cells (25). In this
study, we used VLPs derived from the bacteriophage Q which spontaneously assem-
ble around bacterial RNA following expression in Escherichia coli (26). Q VLPs have
been shown to be immunogenic in clinical studies (27). In addition, we expressed
PvCelTOS as a protein using HEK293T cells, a eukaryotic cell expression system. This
protein was coadministered with Matrix-M, a saponin-based adjuvant that is mixed with
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synthetic cholesterol and a phospholipid and that is thus able to induce both cellular
and humoral immune responses (28). In this study, we evaluated the PvCelTOS-speciﬁc
humoral and cellular immune responses elicited by four different immunization strat-
egies using these platforms. In addition, we analyzed the protective efﬁcacy conferred
by these four vaccination protocols in mice using a novel challenge model employing
a chimeric rodent Plasmodium (P. berghei) parasite (Pb-PvCelTOS). This parasite ex-
presses P. vivax CelTOS in place of the endogenous P. berghei CelTOS. Sporozoites of
these chimeric parasites were used to challenge mice that were previously immunized
with the various vaccine platforms. Moreover, to address the potential cross-species
efﬁcacy afforded by a P. vivax CelTOS vaccine candidate, we made use of a wild-type
P. berghei parasite and a chimeric parasite expressing P. falciparum CelTOS recently
described in the literature (29, 30).
RESULTS
Vaccine platforms targeting PvCelTOS. We developed four vaccine platforms to
induce immune responses directed against PvCelTOS: a recombinant chimpanzee
adenoviral vector (ChAd63) expressing PvCelTOS (Ad), a recombinant MVA vector
expressing PvCelTOS (MVA), PvCelTOS conjugated to bacteriophage Q virus-like par-
ticles (VLPs), and the PvCelTOS protein produced in eukaryotic HEK293T cells (protein).
VLPs and protein were delivered using the Matrix-M adjuvant. To prime immune
responses in BALB/c and CD-1 mice, ChAd63-PvCelTOS was injected intramuscularly.
The other three vaccine platforms were injected intramuscularly 8 weeks later to boost
responses, such that three groups of mice (n  6 each) were immunized with the
following: Ad-MVA, Ad-protein, and Ad-VLPs (Fig. 1A). Serum and peripheral blood
mononuclear cells (PBMCs) were collected 7 days after priming and after boosting to
assess the humoral and cellular immune responses. We followed this prime-boost
approach using a chimpanzee adenovirus followed by other platforms, as it has
previously been described that an initial adenovirus prime can beneﬁt subsequent
boosting immunizations, as well as support the induction of T effector memory (Tem)
cells that correlate with protection upon a sporozoite challenge (31, 32).
Anti-PvCelTOS antibodies induced by prime-boost vaccination regimens. CD-1
mice primed with Ad produced a mean anti-PvCelTOS antibody titer (log10) of 2.44 
0.229 (standard deviation [SD]) 1 week after priming. Antibody levels increased signif-
icantly after boosting with all three vaccine platforms (MVA, VLPs, and protein) (P 
0.001) (Fig. 1B). The MVA boost resulted in a mean titer of 3.32 0.269 (SD), the protein
boost resulted in a mean titer of 3.76  0.211 (SD), and the VLP boost resulted in a
mean titer of 3.63  0.209 (SD). Immunization of BALB/c mice produced similar
antibody responses, with a mean titer of 1.79  0.987 (SD) following Ad priming and
mean titers after boost of 3.09  0.222 (SD) following immunization with Ad-MVA,
4.04  0.185 (SD) with Ad-protein, and 3.78  0.13 (SD) with Ad-VLPs (Fig. 1C). The
titers were signiﬁcantly higher after immunization with MVA (P  0.01), protein (P 
0.001), and VLPs (P  0.001) than after Ad priming. Thus, antibody responses were
boosted with all three vaccine platforms, and boosting with protein in the Matrix-M
adjuvant consistently elicited the highest titers. Although no signiﬁcant differences in
titers were observed between the platforms upon a boost in BALB/c mice, the titer
obtained with Ad-protein was signiﬁcantly higher than that obtained with Ad-MVA in
CD-1 mice.
Anti-PvCelTOS T-cell responses induced by prime-boost vaccination regimens.
PvCelTOS-speciﬁc cellular immune responses were quantiﬁed by ﬂow cytometry after
intracellular cytokine staining (ICS) of PBMCs (Fig. 2 and 3). To this end, blood samples
were collected 7 days after boosting, and PBMCs were isolated and stimulated using
pools of peptides whose sequences spanned the whole PvCelTOS protein sequence.
In CD-1 mice, no signiﬁcant differences in the levels of interleukin-2 (IL-2), tumor
necrosis factor alpha (TNF-), and IFN- production in CD3/CD8 cells were observed
between nonstimulated and stimulated cells either after Ad-protein immunization or
after Ad-VLP immunization (Fig. 2A to C). Peptide stimulation of cells collected after
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Ad-MVA prime-boost, however, induced signiﬁcantly higher TNF- levels than no
stimulation of cells, with the mean values being 2.93%  0.72% (SD) and 0.98% 
0.42% (SD), respectively (P  0.05); likewise, for IFN-, the mean levels were 3.46% 
0.699% (SD) and 1.36%  0.52% (SD) for stimulated and nonstimulated cells, respec-
tively (P  0.05) (Fig. 2B and C). However, the total anti-PvCelTOS cellular responses in
CD-1 mice obtained using this regimen were low when the background values for
nonstimulated cells were subtracted from the values for stimulated cells, resulting in
values of 1.9% for TNF- and 2.1% for IFN-, and only the value of the latter was
signiﬁcantly higher than that for the naive controls (P  0.0001).
In contrast to the ﬁndings obtained with CD-1 mice, all immunization regimens in
BALB/c mice produced substantially higher levels of TNF-- and IFN--producing
CD3/CD8 cells following stimulation with PvCelTOS peptide pools (Fig. 2D to F). The
percentage of TNF--positive cells after stimulation signiﬁcantly increased after boost-
ing with MVA, with means of 10.78%  4.16% (SD) for stimulated cells and 0.468% 
0.314% (SD) for nonstimulated cells (P  0.001); protein boosting gave mean values of
9.58%  4.76% (SD) for stimulated cells and 0.35%  0.17% (SD) for unstimulated cells
(P 0.001), and VLP boosting gave mean values of 11.42% 3.55% (SD) for stimulated
FIG 1 Vaccination regimens and induction of antibody responses against P. vivax CelTOS in outbred CD-1 and inbred BALB/c
mice. (A) Flowchart of the vaccination regimens used in this study. Three groups of 6 mice each were primed with the viral
ChAd63 vector (Ad) expressing PvCelTOS (ChAd63-PvCelTOS). These groups were subsequently boosted with (i) the MVA viral
vector expressing PvCelTOS (MVA-PvCelTOS), (ii) the PvCelTOS protein expressed in eukaryotic HEK293T cells (PvCelTOS), or (iii)
the PvCelTOS protein conjugated to bacteriophage Q VLPs (VLP-PvCelTOS). Blood samples were collected at 14 days after the
Ad prime and at day 63 after the boost. (B) Endpoint titer ELISA showing the total IgG antibody response against recombinant
PvCelTOS protein in CD-1 mice after priming with Ad (day 14) or after boosting with MVA, protein, or VLPs (day 63), as shown
in panel A. Means with standard errors of the means (SEMs) are shown. P values were determined by Tukey’s multiple-
comparison test. *, P  0.05; ****, P  0.0001. (C) Endpoint titer ELISA showing the total IgG antibody response against
recombinant PvCelTOS protein in BALB/c mice after priming with Ad (day 14) or after boosting with MVA, protein, or VLPs (day
63), as shown in panel A. Means with SEMs are shown. P values were determined by Tukey’s multiple-comparison test. **, P 
0.01; ****, P  0.0001.
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FIG 2 (A to F) Ex vivo production of IL-2, TNF-, and IFN- by CD3/CD8 cells upon PvCelTOS stimulation of PBMCs obtained from immunized
CD-1 and BALB/c mice. Samples were collected 1 week after boosting with MVA, protein, and VLPs, as shown in Fig. 1A, and PBMCs were analyzed
with () or without () stimulation with a peptide pool of PvCelTOS (n  3 for naive mice, n  6 for the other groups). (A to C) Frequencies of
CD3/CD8 cells in CD-1 mice producing IL-2 (A), TNF- (B), and IFN- (C); (D to F) frequencies of CD3/CD8 cells in BALB/c mice producing
IL-2 (D), TNF- (E), and IFN- (F). MVA, group boosted with MVA-PvCelTOS; Protein, group boosted with PvCelTOS protein plus the Matrix-M
adjuvant; VLP, group boosted with PvCelTOS coupled to VLPs plus the Matrix-M adjuvant. Means with SEMs are represented. P values were
determined by one-way ANOVA followed by Tukey’s multiple-comparison test. *, P  0.05; ***, P  0.001; ****, P  0.0001. (G) Representative dot
plots showing the production of the three cytokines in the gated CD3/CD8 population obtained from one representative BALB/c mouse
vaccinated with a ChAd63 prime and a boost with MVA expressing PvCelTOS. PerCP, peridinin chlorophyll protein; Comp, compensated; A, area.
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cells and 1.02%  1.45% (SD) for unstimulated cells (P  0.001). Subtraction of the
background values for nonstimulated cells from the values for the stimulated cells gave
mean frequencies of TNF--producing cells of 10.3% with MVA boosting, 9.23% with
protein boosting, and 10.4% with VLP boosting (Fig. 2E). Likewise, the frequency of
IFN--positive cells was also high after boosting with MVA (12.82%  4.50% [SD] and
1.35%  0.40% [SD] for stimulated and unstimulated cells, respectively [P  0.001]),
protein (11.18% 5.55% [SD] and 1.13% 0.28% [SD] for stimulated and unstimulated
cells, respectively [P 0.001]), and VLPs (12.99% 4.33% [SD] and 1.81% 1.54% [SD]
for stimulated and unstimulated cells, respectively [P  0.001]) (Fig. 2F). Subtraction of
the background values for nonstimulated cells from those for stimulated cells gave
mean frequencies of IFN--producing cells of 11.5% with MVA boosting, 10.1% with
protein boosting, and 11.2% with VLP boosting (Fig. 2F). No signiﬁcant difference in the
levels of IL-2 production in CD3/CD8 cells was observed between nonstimulated and
stimulated cells for any immunization regimen.
The induction of PvCelTOS-speciﬁc CD4 T-cell responses was also assessed, but no
signiﬁcant differences in the levels of IL-2, TNF-, and IFN- production by CD3/CD4
cells were observed between nonstimulated and stimulated cells in either CD-1 or
BALB/c mice (Fig. 3).
Protective efﬁcacy induced by prime-boost vaccination regimens. To determine
the protective efﬁcacy of these four vaccination regimens, we developed a rodent
challenge model, which consisted of a chimeric P. berghei parasite line [PbANKA-
PvCelTOS(r)PbCelTOS (Pb-PvCelTOS)] in which the P. berghei celtos coding sequence (CDS)
was replaced with the P. vivax celtos CDS (Pvceltos) (see Fig. S1 in the supplemental
FIG 3 Ex vivo production of IL-2, TNF-, and IFN- by CD3/CD4 cells upon PvCelTOS stimulation of PBMCs obtained from vaccinated CD-1 and
BALB/c mice. Samples were collected 1 week after boosting with MVA, protein, and VLPs, as shown in Fig. 1A, and PBMCs were analyzed with
() or without () stimulation with a peptide pool of PvCelTOS (n  3 for naive mice, n  6 for the other groups). (A to C) Frequencies of
CD3/CD4 cells in CD-1 mice producing IL-2 (A), TNF- (B), and IFN- (C); (D to F) frequencies of CD3/CD8 cells in BALB/c mice producing
IL-2 (D), TNF- (E), and IFN- (F). MVA, group boosted with MVA-PvCelTOS; Protein, group boosted with PvCelTOS protein plus Matrix-M; VLP,
group boosted with PvCelTOS coupled to VLPs plus the Matrix-M adjuvant. Means with SEMs are represented. P values were determined by
one-way ANOVA followed by Tukey’s multiple-comparison test. *, P  0.05.
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material). The parasites with this phenotype displayed normal growth properties and
normal levels of protein expression. Parasite development and ﬁtness are described in
the supplemental material (Fig. S1).
To examine the impact of the different vaccination protocols on protective immu-
nity, the same schedule of prime-boost immunization described above was performed
on BALB/c and CD-1 mice (n  6 mice per group for BALB/c mice and n  10 mice per
group for CD-1 mice). These mice were challenged 10 days after the boost by the
intravenous injection of 1,000 sporozoites either from the newly generated chimeric
Pb-PvCelTOS line or from wild-type P. berghei. In addition, a third set of immunized mice
was challenged with P. berghei sporozoites expressing P. falciparum CelTOS (Fig. 4A to
D) (29, 30). Protective efﬁcacy was determined by measuring the prepatent period after
sporozoite challenge. The prepatent period, deﬁned as the time to reach 1% para-
sitemia after challenge, was calculated using a linear regression based on the three
consecutive thin blood ﬁlms, as described previously (32).
A modest degree of efﬁcacy against challenge with Pb-PvCelTOS was observed in
CD-1 mice after boosting with either protein or VLPs (30% sterile protection); boosting
with MVA protected 10% (1/10) of mice (Fig. 4A; Table 1). The protective efﬁcacies of
the Ad-protein (P 0.0002) and Ad-VLP (P 0.0001) regimens were signiﬁcantly higher
FIG 4 Protective efﬁcacy in BALB/c and CD-1 mice immunized with the different vaccine platforms and challenged with
chimeric and wild-type P. berghei sporozoites. Three groups of 6 BALB/c mice each and nine groups of 10 CD-1 mice each were
primed with the viral vector ChAd63 (Ad) expressing PvCelTOS (ChAd63-PvCelTOS). The groups were subsequently boosted
with (i) the MVA viral vector expressing PvCelTOS (MVA-PvCelTOS), (ii) the PvCelTOS protein expressed in eukaryotic HEK293T
cells (PvCelTOS), and (iii) the PvCelTOS protein conjugated to bacteriophage Q VLPs (VLP-PvCelTOS) (see the ﬂowchart in Fig.
1A). All mice were challenged 66 days after the boost either with wild-type (WT) P. berghei sporozoites or with chimeric
sporozoites expressing PvCelTOS or PfCelTOS (29). (A) Protective efﬁcacy after challenge of immunized CD-1 mice with 1,000
sporozoites of the chimeric parasite line expressing P. vivax CelTOS. Protective efﬁcacy was signiﬁcantly higher for mice
immunized with Ad-protein (P  0.0002) and Ad-VLPs (P  0.0001) than for the naive group (log-rank Mantel-Cox test for
comparison of survival curves). (B) Protective efﬁcacy after challenge of immunized BALB/c mice with 1,000 sporozoites of the
chimeric parasite line expressing P. vivax CelTOS. (C) Protective efﬁcacy after challenge of immunized CD-1 mice with 1,000
sporozoites of the chimeric parasite line expressing P. falciparum CelTOS (29). Protective efﬁcacy was signiﬁcantly higher for
mice immunized with Ad-protein (P  0.0488) than for the naive group (log-rank Mantel-Cox test for comparison of survival
curves). (D) Protective efﬁcacy after challenge of immunized CD-1 mice with 1,000 sporozoites of wild-type P. berghei.
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than the protective efﬁcacy of no treatment, determined by comparison of the survival
of the mice receiving these treatments with the survival of naive mice using a log-rank
Mantel-Cox test to compare the survival curves. In BALB/c mice, no vaccination regimen
conferred any protective efﬁcacy against challenge with Pb-PvCelTOS sporozoites, even
though it induced anti-PvCelTOS antibodies and PvCelTOS-speciﬁc CD8 T cell re-
sponses (Fig. 4B). Conﬁrmation of the lack of efﬁcacy was made in an additional
experiment by using an increased number of mice (Fig. S2). Following a heterologous
challenge with chimeric P. berghei sporozoites expressing P. falciparum CelTOS, 20% of
the CD-1 mice in the protein boost group had complete protective immunity to
infection (Fig. 4C). Protective efﬁcacy was signiﬁcantly higher in mice in this Ad-protein
group than in the group of naive mice (P  0.0488 using a log-rank Mantel-Cox test to
compare survival curves). When a wild-type P. berghei challenge was used, no protec-
tive immunity from any immunization regimen was observed in CD-1 mice (Fig. 4D). A
meta-analysis of the efﬁcacy of the three vaccination regimens indicated that regardless
of the parasite line used for challenge, the Ad-protein vaccine induced the highest
levels of protection (Table 1), and these were signiﬁcantly higher than those induced
using the other immunization regimens (P  0.011, one-way analysis of variance
[ANOVA] with a post hoc Tukey analysis).
DISCUSSION
Efforts are under way to improve the efﬁcacy of subunit vaccines targeting P.
falciparum and P. vivax by testing new adjuvants, vaccination platforms, and antigens
(33). In this study, we investigated the immunogenicity and protective efﬁcacy of the
P. vixax cell-traversal protein for ookinetes and sporozoites (PvCelTOS). CelTOS is a
conserved Plasmodium protein (20) that is expressed in micronemes in both ookinetes
and sporozoites and plays a role in the effective traversal by ookinetes of cells in the
mosquito midgut wall and in sporozoite traversal of hepatocytes (14). As a conse-
quence, CelTOS has a critical role in the establishment of malaria parasite infections in
both the mosquito and the vertebrate host. In both rodent and primate models of
malaria, it has been shown that immunization strategies targeting P. falciparum or P.
berghei CelTOS can enhance protective immunity (16, 17).
Here we extended those studies to the immunogenicity and protective efﬁcacy of
the Plasmodium vivax CelTOS protein. We delivered CelTOS using four clinically relevant
TABLE 1 Summary of efﬁcacy induced by the PvCelTOS vaccination regimens using Ad, MVA, protein, or Q VLPs in mice challenged by
wild-type or transgenic P. berghei sporozoites
Challenge
(1,000 sporozoites) Vaccine regimen Mouse strain
No. of mice
protected/total
no. tested
% of mice
with sterile
protection
Survival duration (days)
Median Range Mean  SD SE
Pb-PvCelTOS,
transgenic
ChAd63-protein CD-1 3/10 30 6.61 6.25–14.0 8.77 3.6 1.14
ChAd63-VLPs CD-1 3/10 30 7.15 5.80–14.0 8.96 3.5 1.11
ChAd63-MVA CD-1 1/10 10 6.33 5.80–14.0 7.12 2.5 0.78
Nonea CD-1 0/10 0 6.105 5.72–6.56 6.09 0.2 0.07
Pb-PfCelTOS,
transgenic
ChAd63-protein CD-1 2/10 20 6.58 5.84–14.0 7.97 3.2 1.01
ChAd63-VLPs CD-1 0/10 0 6.535 6.18–7.76 6.63 0.4 0.14
ChAd63-MVA CD-1 0/10 0 6.365 5.80–7.54 6.44 0.6 0.18
None CD-1 0/10 0 6.085 5.75–6.75 6.18 0.3 0.09
P. berghei wild type ChAd63-protein CD-1 0/20 0 6.59103 5.0–8.0 6.66 0.9 0.31
ChAd63-VLPs CD-1 0/8 0 6.35623 5.0–9.0 6.75 1.2 0.41
ChAd63-MVA CD-1 0/16 0 5.74167 4.99–6.69 5.81 1.2 0.19
None CD-1 0/19 0 6 5.56–7.12 6.13 0.6 0.21
Pb-PvCelTOS,
transgenic
ChAd63-protein BALB/c 0/6 0 5.72106 5.63–7.24 5.99 0.6 0.26
ChAd63-VLPs BALB/c 0/6 0 5.95633 5.56–6.43 5.95 0.3 0.13
ChAd63-MVA BALB/c 0/6 0 5.77731 5.62–6.08 5.82 0.2 0.07
None BALB/c 0/6 0 5.74162 3.84–5.90 5.45 0.8 0.33
aThe mice tested were naive.
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vaccine platforms in a prime-boost vaccine approach, using ChAd63-PvCelTOS (adeno-
virus [Ad]) as the priming agent. We demonstrated the induction of both humoral and
cellular immune responses after immunization of mice with all regimens. However,
despite the induction of anti-PvCelTOS antibodies and PvCelTOS-speciﬁc CD8 T-cell
responses, the various vaccine platforms demonstrated low levels of protective efﬁcacy
against challenge with chimeric P. berghei parasites expressing the PvCelTOS protein.
In this study, PvCelTOS-speciﬁc antibody responses were already evident after a
single prime immunization with ChAd63-PvCelTOS. Antibody levels increased signiﬁ-
cantly after boosting with MVA, VLPs, and protein, with the highest titers being
observed after boosting with VLPs and protein. A previous study using the P. falciparum
CelTOS protein showed that protein vaccination required at least two doses of adju-
vanted protein to induce detectable antibody responses (17). The immunogenicity and
efﬁcacy of protein-based vaccines can be improved by priming with a recombinant Ad
(31). In our study, we observed detectable antibody following priming with Ad injected
intramuscularly without adjuvant. Based on these observations, we decided to use a
vaccination protocol consisting of an initial Ad prime followed by a boost with one of
the three other platforms, VLPs, MVA, or protein. VLPs display antigens in a repetitive
and organized structure and have been shown to induce strong B-cell responses in the
absence of adjuvants by efﬁciently cross-linking speciﬁc receptors on B cells (34). We
found that the conjugate of the CelTOS protein to bacteriophage Q VLPs signiﬁcantly
boosted CelTOS antibody levels to levels comparable to those observed after boosting
with protein adjuvanted with Matrix-M. The Matrix-M adjuvant is safe for use in
humans. It is an immune system-stimulating complex forming 40-nm particles derived
from adjuvant-active saponins, cholesterol, and phospholipids (28). Matrix-M has been
shown to enhance immune responses in humans when combined with inﬂuenza or
West Nile vaccines (35, 36). In our hands, the protein in Matrix-M was as efﬁcient at
boosting antibody responses as protein conjugated to bacteriophage Q VLPs.
As well as inducing good antibody levels, all prime-boost protocols induced high
frequencies of IFN-- and TNF--producing CD8 T cells in BALB/c mice. In contrast,
CD8 T-cell responses were low in CD-1 mice. These observations suggest the existence
of an immunodominant PvCelTOS epitope for inbred BALB/c mice.
The capacity of viral vectors to induce high-magnitude antigen-speciﬁc cellular
immune responses against Plasmodium antigens has been demonstrated both in
animal models (32, 37) and in humans (38, 39). Cellular immunity is essential for
targeting of the liver stage of the parasite’s life cycle (40). A prime-boost regimen using
the viral vectors ChAd63 and MVA has been, to date, the most effective at inducing
high-magnitude cellular immunity in humans (39). Despite the induction of both CD8
T-cell and antibody responses in BALB/c mice, these immune responses did not result
in any protective efﬁcacy against challenge with Pb-PvCelTOS sporozoites with any of
the vaccination regimens. Previous immunization studies have reported high levels of
protective immunity in mice after immunization with both P. falciparum CelTOS and P.
berghei CelTOS (16, 17); protective immunity involved strong cellular and humoral
components. Humoral responses could play an important role to stop the parasite cycle
within the mammalian host, as CelTOS is expressed by the sporozoite and antibodies
could potentially inhibit sporozoite invasion of hepatocytes. Although it was found that
the transfer of increasing doses of CelTOS-speciﬁc antibodies to recipient mice resulted
in incremental protective efﬁcacy, the CelTOS-speciﬁc antibody concentrations in
immunized mice did not directly correlate with the protection status of the mice (16).
This suggests that the quality and the speciﬁcity of the response rather than the
quantity of the response are crucial for achieving antibody-mediated protection. This
may also explain the low levels of protective immunity observed in our studies, despite
good antibody levels. Studies aiming to understand the B-cell epitopes responsible for
the protection conferred by CelTOS can yield important information, and prediction
algorithms coupled to wet lab in vivo models have yielded important information to
contribute to the improvement of anti-CelTOS vaccine approaches (20).
The immunization strategies tested here failed to signiﬁcantly increase the levels of
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IFN-- and TNF--producing CD8 T cells in CD-1 mice. Nevertheless, we observed a
modest level of protection, with 30% of the mice being protected after boosting with
VLPs or protein. This may indicate that protection is mainly mediated by antibody
responses. However, it is important to mention that in our study cellular responses were
assessed by quantifying only the IFN-, TNF-, and IL-2 secreted upon stimulation of
CD4 and CD8 T cells with PvCelTOS-speciﬁc peptides. Thus, it remains possible that
other molecules, such as the cytotoxic marker CD107a, could contribute to protection.
Further experiments using T-cell depletion at the time of the challenge could provide
more evidence on the role of T-cell-mediated immunity. Notwithstanding the role of
other T cells in protective immunity, our studies show that the vaccine platforms used
are incapable of inducing strong protective immune responses in either inbred or
outbred mice. This could be due to a failure to induce speciﬁc antibodies and/or T cells
that recognize critical epitopes, for example, a lack of recognition of conformational
epitopes by the antibodies induced by these vaccination strategies. However, it is also
possible that the B- and T-cell epitopes in P. vivax CelTOS differ from those in P. berghei
and P. falciparum CelTOS, which may explain the differences in protective immunity
observed between our studies and other studies using the CelTOS of P. berghei and P.
falciparum. Interestingly, we observed in CD-1 mice immunized with PvCelTOS modest
protective immunity against challenge with sporozoites expressing P. falciparum Cel-
TOS, suggesting that cross-species protective immune responses were induced with
our vaccine platforms. Further comparative studies, using different vaccine platforms
and using CelTOS from different Plasmodium species, are needed to determine the
value of targeting of CelTOS in a multicomponent subunit vaccine (41). Addition of
adjuvants may also be a means to enhance protection.
MATERIALS AND METHODS
Animals. The age-matched 6-week-old female inbred BALB/c and outbred CD-1 (ICR) strains of mice
used in this study were purchased from Harlan (UK). All animals and procedures were used in accordance
with the terms of the UK Home Ofﬁce Animals Act Project License. Procedures were approved by the
University of Oxford Animal Care and Ethical Review Committee.
Protein expression and puriﬁcation. The mammalian codon-optimized P. vivax celtos gene (Pvcel-
tos; gene identiﬁer, PVX_123510) was cloned into the pHLsec plasmid with the His tag at the 3= end
under the control of the cytomegalovirus enhancer and the chick beta-actin promoter (42). DNA
constructs were produced in E. coli DH5 cells (Life Technologies) and puriﬁed using an endotoxin-free
plasmid megakit (Qiagen). HEK293T cells were transiently transfected using a DNA-polyethylenimine (PEI)
mix. Secreted P. vivax CelTOS (PvCelTOS) protein containing a C-terminal GTK(His6) tag was puriﬁed using
a HisTrap HP 5-ml column (GE Healthcare). The His-tagged PvCelTOS protein was eluted with a 0 to 1 M
imidazole gradient in phosphate-buffered saline (PBS), followed by size exclusion chromatography in 20
mM Tris-HCl, pH 8.0, 300 mM NaCl. The size and purity of the puriﬁed protein were veriﬁed with colloidal
Coomassie blue for total protein staining.
Viral vector vaccines. The mammalian codon-optimized P. vivax celtos gene (Pvceltos; gene iden-
tiﬁer, PVX_123510) was cloned into the chimpanzee adenovirus ChAd63, and virus was grown on
HEK293T cells as described earlier (43). The ﬁnal concentration of the virus stock was 8.06  109
infectious units (IU)/ml and 5.15  1011 viral particles/ml, for a ratio of the number of viral particles/
number of PFU of 1:63.9.
The same PvCelTOS sequence was used to develop recombinant modiﬁed vaccinia virus Ankara
(MVA) expressing the PvCelTOS protein. The ﬁnal concentration of the virus stock was 1.7  109 PFU/ml.
Coupling of the PvCelTOS protein to bacteriophage Q VLPs. Virus-like particles (VLPs) derived
from bacteriophage Q were expressed in E. coli JM109 containing the expression plasmid pQ10 and
puriﬁed as described previously (44). The PvCelTOS protein was covalently conjugated to Q by a
two-step procedure. First, Q VLPs (2 mg/ml in PBS, pH 7.2) were incubated at room temperature (RT)
for 30 min in the presence of a 7.5-fold molar excess of the heterobifunctional chemical cross-linker
succinimidyl-6-(-maleimidopropionamido) hexanoate (SMPH). Unreacted SMPH cross-linker was re-
moved by diaﬁltration against PBS (pH 7.2) using 100-kDa Amicon Ultra centrifugal ﬁlters (Millipore). Prior
to the conjugation step, puriﬁed PvCelTOS was incubated for 30 min at room temperature with a 6-fold
molar excess of N-succinimidyl-S-acetylthioacetate (SATA), excess SATA cross-linker was removed by
diaﬁltration as before using 3-kDa Amicon Ultra centrifugal ﬁlters (Millipore), and derivatized protein was
then deprotected using hydroxylamine (3 h at room temperature), resulting in the addition of reactive
sulfhydryl residues to the protein. Following a further diaﬁltration, PvCelTOS-SATA was covalently linked
to the derivatized Q by reacting equimolar amounts of PvCelTOS-SATA and Q-SMPH for 4 h at room
temperature. The conjugated VLP vaccine was analyzed by SDS-PAGE, and the intensities of the
Coomassie blue-stained bands corresponding to the various components of the coupling reaction were
determined by densitometry and used to calculate coupling efﬁciency. Q-VLP is composed of 180
copies of the 132-amino-acid coat protein monomer. Monomeric, derivatized Q migrated as a discrete
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15-kDa band, while the Q-PvCelTOS conjugate migrated at 36 kDa (the 15-kDa Q monomer plus the
21-kDa PvCelTOS). Coupling efﬁciency was deﬁned as the molar ratio of Q monomers coupled to
PvCelTOS (the 21-kDa band) to total Q monomers (the sum of the 15- and 21-kDa bands). The coupling
efﬁciency calculated in this way is a minimum estimate of the degree of coupling, as it does not take into
account Q monomers coupled to more than one PvCelTOS molecule.
Immunization of mice. Prior to immunization, the animals were anesthetized using an inhalation
chamber containing a mixture of gases comprising isoﬂurane (23.5%) and oxygen (12 liters/min). Mice
were initially immunized (primed) with simian adenoviral vector 63 (ChAd63) encoding the PvCelTOS
gene at a dose of 1  108 IU.
At 8 weeks after priming, mice were boosted with PvCelTOS-MVA, PvCelTOS-protein, or PvCelTOS-
VLPs. Boosting with PvCelTOS-MVA was performed at a concentration of 1  106 PFU per ml. All viral
vector vaccines were administered intramuscularly in endotoxin-free PBS in both limbs. All recombinant
ChAd63 and MVA viral vectors used throughout this study were generated at The Jenner Institute’s
vector core facility.
The PvCelTOS protein dissolved in PBS with Matrix-M adjuvant was administered intramuscularly.
Matrix-M (Isconova, Sweden [now Novavax, MD, USA]) was mixed and brieﬂy vortexed with the PvCelTOS
protein at 15 g per dose. The adjuvant was kindly provided by Novavax, MD, USA.
The PvCelTOS protein associated with bacteriophage Q VLPs was administered intramuscularly as
a 50-l dose containing sterile PBS and 15 g of protein mixed with 10 g of Matrix-M adjuvant.
Challenge of immunized mice. At 14 days after the boost, mice were challenged by intravenous
injection of 1,000 chimeric or wild-type P. berghei sporozoites. Efﬁcacy was assessed by calculating the
prepatent period (i.e., the time to reach 1% parasitemia), as described earlier (32).
Infection of mice, sporozoite production, and isolation of sporozoites were performed as described
previously (43).
Generation of DNA constructs and genotyping of chimeric parasites expressing PvCelTOS. To
generate the chimeric parasites where the P. berghei celtos (Pbceltos) coding sequence (CDS; gene
identiﬁer, PBANKA_1432300) was replaced by the P. vivax celtos (Pvceltos) CDS (gene identiﬁer,
PVX_123510), we used a 2-step gene insertion/marker out (GIMO) transfection protocol (45, 46). In the
ﬁrst step, we deleted the Pbceltos CDS and replaced it with the positive-negative selectable marker to
create a P. berghei celtos deletion GIMO line (PbANKA-CelTOS GIMO). To do this, we generated the pL1960
construct, which is based on the standard GIMO DNA construct pL0034 (45). This construct contains the
positive-negative human dihydrofolate reductase:yeast ﬂuorocytosine uridyl (hdhfr::yfcu) selection
marker (SM) cassette and was used to insert both the Pbceltos 5= and 3= gene targeting regions (TRs),
encompassing the full-length promoter and the transcription terminator sequences, respectively. The
linear pL1960 DNA construct was introduced into PbGFP-Luccon parasites (line 676m1cl1) using standard
methods of transfection (47). Transfected parasites were selected in mice by applying positive selection
by providing pyrimethamine in the drinking water (47). Transfected parasites were cloned by limiting
dilution (48), resulting in the PbANKA-CelTOS GIMO line (line 2217). Correct deletion of the Pbceltos CDS
was conﬁrmed by diagnostic PCR analysis of genomic DNA (gDNA) and Southern analysis of pulsed-ﬁeld
gel (PFG)-separated chromosomes as described previously (47). The primers used for PCR genotyping are
listed in Fig. S1 in the supplemental material.
In the second step, we replaced the positive-negative SM in the PbANKA-CelTOS GIMO genome with
the Pvceltos CDS by GIMO transfection to create the P. berghei chimeric CelTOS replacement line. This was
achieved by modifying the construct used in the ﬁrst step (pL1960); the hdfhr::yfcu SM cassette was
removed and replaced with the Pvceltos CDS sequence, generating the plasmid pL2017. The Pvceltos CDS
was ampliﬁed from the DNA of a P. vivax SalI strain (Pvceltos; gene identiﬁer, PVX_123510). The pL2017
construct was sequenced to ensure that there were no mutations in the Pvceltos CDS. The construct was
linearized using ApaI and NotI restriction enzymes outside the 5= and 3= TRs before transfection. The
construct was used to transfect parasites of a PbANKA-CelTOS GIMO line (line 2217cl1) using standard
methods of GIMO transfection (45). Transfected parasites were selected in mice by applying negative
selection by providing 5-ﬂuorocytosine (5-FC) in the drinking water of the mice (46). Negative selection
results in the selection of chimeric parasites where the hdhfr::yfcu SM in the celtos locus of the
PbANKA-CelTOS GIMO line is replaced by the CDS of Pvceltos. Selected chimeric parasites were cloned by
the method of limiting dilution. Correct integration of the constructs into the genome of chimeric
parasites was analyzed by diagnostic PCR analysis on gDNA and Southern analysis of PFG-separated
chromosomes as described previously (47). The primers used for PCR genotyping are listed in Fig. S1. This
method creates chimeric gene replacement P. berghei parasites that lack the Pbceltos CDS but express
PvCelTOS [PbANKA-PvCelTOS(r)PbCelTOS; line 2320cl2] under the control of the Pbceltos regulatory se-
quences.
Phenotype characterization of chimeric parasites expressing PvCelTOS. Expression of PvCelTOS
in the chimeric sporozoites was analyzed by immunoﬂuorescence assay (IFA), using sera from mice
immunized with the PvCelTOS protein (diluted 1:100). Puriﬁed sporozoites were ﬁxed with 4% parafor-
maldehyde in PBS for 20 min on ice and then washed three times with PBS and blocked with 20 l 10%
fetal calf serum (FCS) plus 1% bovine serum albumin (BSA) in PBS for 30 min at room temperature. Upon
removal of the blocking medium, samples were incubated in a volume of 20 to 25 l of the antiserum
described above in 10% FCS plus 1% BSA in PBS (blocking medium) for 1 to 2 h at room temperature
or overnight at 4°C. After incubation with the primary antibody, the slides were washed three times with
PBS, followed by the staining with the secondary antibody Alexa Fluor 488 goat anti-mouse IgG (Life
Technologies). Samples were washed three times with PBS, and nuclei were stained with Hoechst 33342
(Cell Signaling Technology) at a concentration of 2% in PBS for 10 min at room temperature, washed
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twice with PBS, and left to air dry, followed by addition of ﬂuorescence mounting medium (Dako).
Coverslips were mounted onto the slides, and the slides were sealed with nail polish and left to dry
overnight in the dark. The parasites in both the blue and green channels were analyzed using a DMI-300B
Leica ﬂuorescence microscope, and images were processed using ImageJ software (Fig. S1).
Peptides. Fifteen-mer peptides overlapping by 10 amino acids spanning the whole sequence of P.
vivax CelTOS were synthesized by Mimotopes Pty, Ltd., Australia. The peptides were dissolved in dimethyl
sulfoxide at a concentration of 50 mg/ml and combined into a single pool for their use in intracellular
cytokine staining (ICS) assays (see below) to a ﬁnal peptide concentration of 5 g/ml.
ICS assays. For ICS, ammonium chloride-potassium (ACK) lysis buffer-treated whole-blood PBMCs
were resuspended in complete Dulbecco modiﬁed Eagle medium with 10% BSA containing 1 l/ml
GolgiPlug protein transport inhibitor and monensin and incubated for 10 h in the presence or absence
of a peptide pool representing the PvCelTOS antigen at individual peptide concentrations of 5 g/ml.
Phenotypic analysis of CD3, CD4, and CD8 T cells was performed by staining PBMCs using the
following antibodies: anti-mouse CD3e phycoerythrin (PE)-Cy5 (clone 145-2C11), anti-mouse CD8 peri-
dinin chlorophyll protein-Cy5.5 (clone 53-6.7), and anti-mouse CD4 allophycocyanin (APC)-eFluor 780
(clone GK1.5); all of these antibodies were from eBioscience. For IFN-, TNF-, and IL-2 cytokine staining,
the following antibody clones were used: APC-conjugated rat anti-mouse IFN- (clone XMG1.2), Alexa
Fluor 488-conjugated rat anti-mouse TNF (clone MP6-XT22), and PE-Cy7-conjugated rat anti-mouse IL-2
(clone JES6-5H4); all these clones were from BD Pharmingen. Viable cells were selected and gated using
staining with stain from a Live/Dead ﬁxable red dead cell stain kit for excitation at 488 nm (Life
Technologies). Flow cytometric analyses were performed using an LSRII instrument. Data were analyzed
using either FACSDiva or FlowJo software. Analysis of multifunctional CD8 and CD4 T-cell responses
was performed using Boolean analysis in FlowJo software.
Whole-IgG ELISA. Enzyme-linked immunosorbent assay (ELISA) plates (F96 MaxiSorp Nunc immu-
noplates) were coated with 1 g/ml PvCelTOS protein (Pvceltos; gene identiﬁer, PVX_123510) produced
in HEK293T cells and puriﬁed as described above. Protein was diluted in PBS (50 l per well), incubated
at RT overnight, washed 6 times with PBS–0.05% Tween 20 (PBS-T), and blocked with PBS-T containing
10% skimmed milk (100 l per well) for 1 h at RT. The serum was diluted 1:15,000 in PBS-T and added
to duplicate wells. A standard curve was prepared with serum positive for antibodies against PvCelTOS
in the starting solution serially diluted 3-fold in PBS-T, and the dilutions were placed down the plate.
Naive and positive serum samples were included as controls, and the samples were incubated for 2 h at
RT. After incubation, the plates were washed 6 times with PBS-T. The antibody goat anti-mouse whole
IgG-alkaline phosphatase conjugate (catalog number A-3562; Sigma), diluted 1:5,000 in PBS-T (50 l per
well), was added, and the plates were incubated for 1 h at RT. After incubation with anti-mouse IgG, the
plates were washed 6 times with PBS-T. Then, p-nitrophenyl phosphate (pNPP) substrate dissolved in
diethanolamine buffer (100 l per well) was added, and the plates were incubated for 13 min at RT to
allow development of the reaction. The reaction product absorbed light at 405 nm and was read on a
CLARIOstar ELISA microplate reader.
Statistical analyses. A repeated-measure one-way ANOVA was used for comparisons among larger
groups, followed by Tukey’s multiple-comparison test. The Kolmogorov-Smirnov test for normality was
used to determine whether the values followed a Gaussian distribution. The Mantel-Cox test was used
to represent protective efﬁcacy against challenge with chimeric P. berghei. A P value of 0.05 was
considered statistically signiﬁcant. GraphPad Prism software (San Diego, CA, USA) was used for all
statistical tests.
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